Stay updated on Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check2 days agoChange DetectedA minor revision update was applied: Revision: v3.3.4 replacing v3.3.3. This metadata change does not affect the study details, eligibility criteria, endpoints, or user-facing content on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedExpanded the study locations by adding numerous site locations across the US, Argentina, Australia, and Europe, broadening enrollment options. Removed the HHS Vulnerability Disclosure entry and several location groups.SummaryDifference4%

- Check52 days agoChange DetectedPublications section description updated to note that entries are automatically filled from PubMed and may not be about the study. Revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check59 days agoChange DetectedRemoved the prominent notice stating that information on the site may not be up to date due to a lapse in government funding. The notice previously advised users to check cc.nih.gov and opm.gov for operating status updates.SummaryDifference0.1%

- Check73 days agoChange DetectedThe changes appear to be cosmetic, involving layout adjustments on the Study Details page, with no changes to core content such as eligibility criteria, endpoints, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check102 days agoChange DetectedMajor update to page content: introduces a government funding/status notice and current operating status for NIH Clinical Center, and updates the version from v3.1.0 to v3.2.0.SummaryDifference2%

Stay in the know with updates to Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.